GLOBOCAN 2012. Estimated cancer incidence, mortality and prevalence worlwide in 2012 http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. 2012.
Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460(3):237–49. doi:10.1007/s00428-012-1203-5.
Article
PubMed
Google Scholar
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.21254.
Article
PubMed
Google Scholar
Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014;6(5):229–39. doi:10.1177/1758834014544121.
Article
CAS
PubMed
PubMed Central
Google Scholar
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–9. doi:10.1038/nm1093.
Article
CAS
PubMed
Google Scholar
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8(+) tumor-infiltrating lymphocytes and a high CD8(+)/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538–43. doi:10.1073/pnas.0509182102.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–13. doi:10.1056/Nejmoa020177.
Article
CAS
PubMed
Google Scholar
Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104(9):3360–5. doi:10.1073/pnas.0611533104.
Kandalaft LE, Facciabene A, Buckanovich RJ, Coukos G. Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res. 2009;15(14):4521–8. doi:10.1158/1078-0432.CCR-08-0543.
Article
CAS
PubMed
PubMed Central
Google Scholar
Berlin C, Kowalewski DJ, Schuster H, Mirza N, Walz S, Handel M, et al. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia. 2015;29(3):647–59. doi:10.1038/leu.2014.233.
Article
CAS
PubMed
Google Scholar
Goswami M, Hensel N, Smith BD, Prince GT, Qin L, Levitsky HI, et al. Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues. Leukemia. 2014;28(5):1167–70. doi:10.1038/leu.2014.14.
Article
CAS
PubMed
PubMed Central
Google Scholar
Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Immunity and immune suppression in human ovarian cancer. Immunotherapy. 2011;3(4):539–56. doi:10.2217/Imt.11.20.
Article
PubMed
PubMed Central
Google Scholar
Chianese-Bullock KA, Irvin WP, Petroni GR, Murphy C, Smolkin M, Olson WC, et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother. 2008;31(4):420–30. doi:10.1097/Cji.0b013e31816dad10.
Article
CAS
PubMed
Google Scholar
Chiriva-Internati M, Weidanz JA, Yu Y, Frezza EE, Jenkins MR, Kennedy RC, et al. Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer. J Immunother. 2008;31(8):693–703. doi:10.1097/Cji.0b013e31818283d5.
Article
CAS
PubMed
Google Scholar
Diefenbach CSM, Gnjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res. 2008;14(9):2740–8. doi:10.1158/1078-0432.Ccr-07-4619.
Article
CAS
PubMed
Google Scholar
Hung CF, Wu TC, Monie A, Roden R. Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev. 2008;222:43–69. doi:10.1111/j.1600-065X.2008.00622.x.
Article
CAS
PubMed
PubMed Central
Google Scholar
Leisegang M, Wilde S, Spranger S, Milosevic S, Frankenberger B, Uckert W, et al. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J Clin Invest. 2010;120(11):3869–77. doi:10.1172/Jci43437.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vermeij R, Daemen T, de Bock GH, de Graeff P, Leffers N, Lambeck A et al. Potential target antigens for a universal vaccine in epithelial ovarian cancer. Clin Dev Immunol. 2010;2010. doi:10.1155/2010/891505.
Ochsenreither S, Majeti R, Schmitt T, Stirewalt D, Keilholz U, Loeb KR, et al. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood. 2012;119(23):5492–501. doi:10.1182/blood-2011-07-365890.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rivera A, Mavila A, Bayless KJ, Davis GE, Maxwell SA. Cyclin A1 is a p53-induced gene that mediates apoptosis, G2/M arrest, and mitotic catastrophe in renal, ovarian, and lung carcinoma cells. Cell Mol Life Sci. 2006;63(12):1425–39. doi:10.1007/s00018-006-5521-5.
Article
CAS
PubMed
Google Scholar
Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA. 2001;98(1):31–6. doi:10.1073/pnas.011404098.
Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012;19(2):197–208. doi:10.1530/Erc-11-0329.
Article
CAS
PubMed
Google Scholar
Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198–208. doi:10.1158/1078-0432.CCR-08-0196.
Article
CAS
PubMed
Google Scholar
Muller-Tidow C, Diederichs S, Schrader MG, Vogt U, Miller K, Berdel WE, et al. Cyclin A1 is highly expressed in aggressive testicular germ cell tumors. Cancer Lett. 2003;190(1):89–95. doi:10.1016/S0304-3835(02)00582-7.
Article
CAS
PubMed
Google Scholar
Kim JE, Jang MJ, Jin DH, Chung YH, Choi BS, Park GB, et al. Paclitaxel-exposed ovarian cancer cells induce cancerspecific CD4+ T cells after doxorubicin exposure through regulation of MyD88 expression. Int J Oncol. 2014;44(5):1716–26. doi:10.3892/ijo.2014.2308.
CAS
PubMed
Google Scholar
Law KS, Chen HC, Liao SK. Non-cytotoxic and sublethal paclitaxel treatment potentiates the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lymphokine-activated killer cells. Anticancer Res. 2007;27(2):841–50.
CAS
PubMed
Google Scholar
Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323–37. doi:10.1158/1078-0432.CCR-09-0737.
Article
PubMed
Google Scholar
Coletta RD, Christensen K, Reichenberger KJ, Lamb J, Micomonaco D, Huang L, et al. The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci U S A. 2004;101(17):6478–83. doi:10.1073/pnas.0401139101.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ji P, Agrawal S, Diederichs S, Baumer N, Becker A, Cauvet T, et al. Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells. Oncogene. 2005;24(16):2739–44. doi:10.1038/sj.onc.1208356.
Article
CAS
PubMed
Google Scholar
Kim J, Kim WJ, Liu Z, Loda M, Freeman MR. The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle. 2012;11(6):1123–30. doi:10.4161/cc.11.6.19550.
Article
CAS
PubMed
PubMed Central
Google Scholar
Marlow LA, von Roemeling CA, Cooper SJ, Zhang YL, Rohl SD, Arora S, et al. Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies. J Cell Sci. 2012;125(18):4253–63. doi:10.1242/Jcs.097428.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wegiel B, Bjartell A, Culig Z, Persson JL. Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer. 2008;122(7):1521–9. doi:10.1002/ijc.23261.
Article
CAS
PubMed
Google Scholar
Ekberg J, Persson JL. Post-translational modification of cyclin A1 is associated with staurosporine and TNFalpha induced apoptosis in leukemic cells. Mol Cell Biochem. 2009;320(1–2):115–24. doi:10.1007/s11010-008-9913-3.
Article
CAS
PubMed
Google Scholar
Restle A, Farber M, Baumann C, Bohringer M, Scheidtmann KH, Muller-Tidow C, et al. Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants. Nucleic Acids Res. 2008;36(16):5362–75. doi:10.1093/nar/gkn503.
Article
CAS
PubMed
PubMed Central
Google Scholar
Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RCF, Kelly KF, et al. P53 mutation is a common genetic event in ovarian-carcinoma. Cancer Res. 1993;53(9):2128–32.
CAS
PubMed
Google Scholar
Osborne RJ, Leech V. Polymerase chain reaction allelotyping of human ovarian cancer. Br J Cancer. 1994;69(3):429–38.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang R, Muller C, Huynh V, Fung YK, Yee AS, Koeffler HP. Functions of cyclin A1 in the cell cycle and its interactions with transcription factor E2F-1 and the Rb family of proteins. Mol Cell Biol. 1999;19(3):2400–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bali A, O’Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res. 2004;10(15):5168–77. doi:10.1158/1078-0432.CCR-03-0751.
Article
CAS
PubMed
Google Scholar
Dong Y, Walsh MD, McGuckin MA, Cummings MC, Gabrielli BG, Wright GR, et al. Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer. 1997;74(4):407–15.
Article
CAS
PubMed
Google Scholar
Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res. 2001;7(10):2984–97.
CAS
PubMed
Google Scholar
Suh DS, Yoon MS, Choi KU, Kim JY. Significance of E2F-1 overexpression in epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18(3):492–8. doi:10.1111/j.1525-1438.2007.01044.x.
Article
CAS
PubMed
Google Scholar
Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, et al. Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol. 2013;130(3):565–9. doi:10.1016/j.ygyno.2013.06.016.
Article
CAS
PubMed
PubMed Central
Google Scholar
Muller C, Yang R, Idos G, Tidow N, Diederichs S, Koch OM, et al. c-myb transactivates the human cyclin A1 promoter and induces cyclin A1 gene expression. Blood. 1999;94(12):4255–62.
CAS
PubMed
Google Scholar
Muller C, Yang R, Park DJ, Serve H, Berdel WE, Koeffler HP. The aberrant fusion proteins PML-RAR alpha and PLZF-RAR alpha contribute to the overexpression of cyclin A1 in acute promyelocytic leukemia. Blood. 2000;96(12):3894–9.
CAS
PubMed
Google Scholar